ArticleProceedings (Baylor University. Medical Center)2025
Efficacy and safety of nirsevimab for preventing respiratory syncytial virus infection in infants: an updated systematic review and meta-analysis encompassing 11,001 participants.
Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Respiratory Pathogen Co-Detection in Hospitalized Infants with Bronchiolitis and Implementation of Universal Nirsevimab Immunoprophylaxis: A Six-Year Observational Study.Children (Basel, Switzerland) · 2026Article
- Review
- Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months.Children (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) is recognized as the leading cause of lower respiratory tract infections (LRTI) and a major contributor to newborn hospitalizations. Recent clinical trials have demonstrated the effectiveness of nirsevimab in preventing RSV infections among infants. This meta-analysis evaluated the efficacy and safety of nirsevimab in healthy infants born at varying gestational ages during their first RSV season. Methods: Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched electronic databases-PubMed, SCOPUS, Cochrane Library, and Web of Science-to identify relevant studies published up to March 2025. Results: We included three studies with 11,001 participants. Nirsevimab was significantly associated with decreased hospitalization for LRTI due to RSV (risk ratio [RR]: 0.21; 95% confidence interval [CI] 0.13, 0.33; Conclusion: Nirsevimab shows promise in preventing RSV infections and hospitalizations, warranting further study on its practicality and cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.